Opko Health (OPK) Tops Q2 EPS by 3c

Opko Health (NYSE: OPK) reported Q2 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $23.7 million.

"In the second quarter, we continued to make strides in converting our advanced pipeline of diagnostic and pharmaceutical products into commercial successes,” said Phillip Frost, M.D., Chairman and CEO. “The 4Kscore Test is being increasingly adopted by Urologists because of its utility for identifying patients at the greatest risk of having high-grade prostate cancer and clinical trials of Rayaldee, hGH-CTP and Rolapitant have all provided the anticipated evidence of safety and efficacy. We look forward to making these important products available as rapidly as possible to patients who will benefit from their use.”

For earnings history and earnings-related data on Opko Health (OPK) click here.

You May Also Be Interested In

• SAP Q1 results fall short of Wall Street estimates as transformation kicks off
• Ameriprise Financial's quarterly profit rises on higher fees, AUM
• Nucor (NUE) Misses Q1 EPS by 21c